Hours after disclosing late-day news June 30 that his company's Feraheme at last won approval from the FDA, an exhilarated Brian J.G. Pereira, president and CEO of AMAG Pharmaceuticals Inc., told BioWorld Insight the iron-replacement would be priced "at a premium" to others on the market.
The lukewarm day-one reception on Wall Street last week for Myriad Genetics Inc.'s spin-off of Myriad Pharmaceuticals Inc. foretells neither the success of the new firm nor of similar models tried by other companies, but it does sharpen the points on some of the questions raised by those earlier attempts - and shows what a difference timing can make.
Mixed interim Phase II data with Prochymal chronic obstructive pulmonary disease - good safety, not-so-great efficacy - laid a ball of confusion on Wall Street's doorstep that prompted sharply differing opinions about the future of the adult mesenchymal stem cell candidate from Osiris Therapeutics Inc.
